AI Article Synopsis
- The study aimed to explore the effects of chronic kidney disease (CKD) on high-on treatment platelet reactivity (HRPR) in patients taking ticagrelor after acute coronary syndrome (ACS) treatment.
- The research included 396 patients and found that CKD did not significantly affect platelet reactivity or the occurrence of major cardiovascular events over an average follow-up period of around 939 days.
- The results indicate that renal failure does not increase the risk of high platelet reactivity or adverse outcomes, suggesting similar safety profiles for CKD and non-CKD patients on dual antiplatelet therapy.
Article Abstract
Background: No study has so far evaluated the impact of chronic kidney disease (CKD) on high-on treatment platelet reactivity (HRPR) with ticagrelor and their prognostic consequences, that were therefore the aim of the present study.
Methods: Patients on dual antiplatelet therapy with ASA+ticagrelor (90mg/twice a day) after percutaneous coronary revascularization for ACS were scheduled for platelet function assessment 30-90 days post-discharge. The primary study endpoint was defined as the occurrence of major cardiovascular events (a composite of cardiovascular death, recurrent acute coronary syndrome (MI), target vessel revascularization) at the longest available follow-up.
Results: We included 396 patients, that were divided according to CKD (eGFR
Conclusions: In the present study we demonstrated that among ACS patients on DAPT with ASA and ticagrelor after PCI, renal failure is not associated with a higher rate of HRPR or to an increased risk of mortality or major ischemic and bleeding events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S2724-5683.22.06001-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!